Palatin Technologies
Palatin Technologies develops novel therapeutics targeting inflammatory and autoimmune conditions, leveraging the melanocortin system to design treatments for diseases such as Dry Eye Disease and ulcerative colitis.
Services
Palatin Technologies focuses on developing novel therapeutics for patients with inflammatory and autoimmune conditions. The company leverages its understanding of the melanocortin system to create therapeutics that engage natural pathways to resolve harmful inflammation. The primary focus is on ocular diseases, but the company's scope also includes treatments for diabetic nephropathy and obesity.
Products
Palatin Technologies has developed Vyleesi® (bremelanotide injection) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Vyleesi® is notable for being the first FDA-approved melanocortin agent. Other products in development include PL9643, a melanocortin receptor agonist in Phase 3 clinical development for Dry Eye Disease, and PL9654, which is being developed for retinal diseases with intravenous and topical delivery methods.
Current Clinical Trials
Palatin Technologies is actively conducting clinical trials for multiple drugs. PL9643 is in Phase 3 clinical development for Dry Eye Disease, and PL8177, an oral melanocortin receptor 1 (MCR1) agonist, is in Phase 2 clinical trials for ulcerative colitis. The company is also exploring the use of PL9654 for retinal diseases, utilizing both intravenous (IVT) and topical delivery methods.
Sector
Palatin Technologies operates in the biopharmaceutical sector, focusing on the development of receptor-selective melanocortin agonists for the treatment of inflammatory and autoimmune conditions. The company's expertise lies in creating therapies that can prevent and reverse inflammation in disease models, particularly within ocular, intestinal, and systemic contexts.
Location and Headquarters
Palatin Technologies is headquartered at 4-B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512. From this location, the company conducts its research, development, and clinical trials aimed at addressing the unmet needs of patients living with inflammatory and autoimmune diseases.